Non-Small-Cell Lung Cancer (NSCLC) Market to Observe Stupendous Growth During the Forecast Period – DelveInsight | Immutep Limited (eftilagimod alpha), Daiichi Sankyo, Novartis, Mirati Therapeutic

October 05 22:27 2022
Non-Small-Cell Lung Cancer (NSCLC) Market to Observe Stupendous Growth During the Forecast Period - DelveInsight | Immutep Limited (eftilagimod alpha), Daiichi Sankyo, Novartis, Mirati Therapeutic
Delveinsight Business Research LLP
As per DelveInsight, the Non-Small Cell Lung Cancer (NSCLC) market size is anticipated to transform in the coming years owing to the increasing incident case of NSCLC, continued uptake of approved therapies (mainly immune checkpoint inhibitors), expected entry of potential premium price emerging therapies, and increasing awareness of mutations like BRAF, c-Met, and others.

Globally, about 135+ key pharma and biotech companies are working in the Non-Small-Cell Lung cancer (NSCLC) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

DelveInsight’s “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Non-Small Cell Lung Cancer Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Non-Small Cell Lung Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Non-Small Cell Lung Cancer Market

Non-Small-Cell Lung Cancer (NSCLC): An Overview

NSCLC is the most common type of lung cancer, accounting for approximately 85% of all lung cancers. However, NSCLC metastasizes to other organs slower in comparison to SCLC, and microscopically, SCLC is composed of much smaller cells. NSCLC is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas, and several other types that occur less frequently, including adenosquamous carcinomas and sarcomatoid carcinomas.

Patients of NSCLC with resectable disease may be cured by surgery or surgery followed by chemotherapy. Local control can be achieved by radiation therapy in a large number of patients with unresectable diseases. On the other hand, patients with the locally advanced unresectable disease may achieve long-term survival with radiation therapy combined with chemotherapy, and patients with advanced metastatic disease may achieve improved survival and palliation of symptoms with chemotherapy, targeted agents, and other supportive measures

Currently, the mainstay of treatment is immune checkpoint inhibitors, a combination of targeted and immunotherapy with chemotherapy. Although in the future, the scenario will change as most companies are targeting specific mutations to treat NSCLC patients.

Non-Small-Cell Lung Cancer (NSCLC) Market Key Facts

  • As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 in the year 2017. These cases are expected to grow with a significant CAGR in the study period.

  • As per the DelveInsight estimates, the total incident cases of NSCLC patients by histology in Germany were observed to be 16,506, 26,409, 6,602, and 6,602 cases of squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and others in the year 2017.

  • According to the American Cancer Society, out of the total lung cancer cases, approximately 80─85% of lung cancers are NSCLC. The main subtypes of NSCLC include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

  • According to the SEER, if the cancer is found only in the part of the body where it started, it is localized (sometimes referred to as Stage I ). If it has spread to a different part of the body, the stage is regional or distant. The stage-specific cases of NSCLC are 16%, 22%, 57%, and 4% for the localized, regional, distant, and unknown stages. 

Non-Small-Cell Lung Cancer (NSCLC) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Non-Small Cell Lung Cancer market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Non-Small Cell Lung Cancer market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Non-Small-Cell Lung Cancer (NSCLC) Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Non-Small-Cell Lung Cancer (NSCLC) Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Non-Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Non-Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Recent Developments in the Non-Small-Cell Lung Cancer (NSCLC) Therapeutics Market

In May 2022, BridgeBio Pharma and Bristol Myers Squibb (BMS) entered an exclusive license agreement for developing and marketing BBP-398 in oncology. An inhibitor of SHP2, BBP-398, was created through a partnership with the Therapeutics Discovery division of The University of Texas MD Anderson Cancer Center, US. Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.

On October 04, 2022, Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the US FDA had granted Fast Track designation to eftilagimod alpha (“efti” or “IMP321”) in combination with pembrolizumab for the treatment of 1st line non-small cell lung cancer (NSCLC).

Learn How Non-Small Cell Lung Cancer Market Will Evolve by 2032 @

Non-Small-Cell Lung Cancer (NSCLC) Therapeutics Analysis

The Non-small cell lung cancer (NSCLC) market dynamics are anticipated to change in the coming years owing to the rise in healthcare spending across the world and the launch of emerging therapies.

Some of the key companies in the Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market include:

BridgeBio Pharma, Daiichi Sankyo,  EMD Serono/Merck,  BridgeBio Pharma,  Abbvie/Pfizer,  Eli Lilly and Company,  BioNTech SE,  Shenzhen TargetRx,  Taiho Pharmaceutical,  Chong Kun Dang,  Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical,  Bayer,  GeneScience Pharmaceuticals,  InventisBio,  Apollomics,  Imugene,  Ono Pharmaceutical/Pierre Fabre,  Jiangsu Hengrui Medicine Co.,  Bristol-Myers Squibb, Surface Oncology, Inhibrx,  Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines,  Yong Shun Technology Development,  Iovance Biotherapeutics,  Galecto Biotech, and others.

Non-Small-Cell Lung Cancer (NSCLC) Drugs Covered in the report include

• Datopotamab deruxtecan: Daiichi Sankyo 

• JDQ443: Novartis 

• MRTX849: Mirati Therapeutics

• INBRX-106: Inhibrx

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Non-Small Cell Lung Cancer Competitive Intelligence Analysis

4. Non-Small Cell Lung Cancer Market Overview at a Glance

5. Non-Small Cell Lung Cancer Disease Background and Overview

6. Non-Small Cell Lung Cancer Patient Journey

7. Non-Small Cell Lung Cancer Epidemiology and Patient Population (In US, EU5, and Japan)

8. Non-Small Cell Lung Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Non-Small Cell Lung Cancer Unmet Needs

10. Key Endpoints of Non-Small Cell Lung Cancer Treatment

11. Non-Small Cell Lung Cancer Marketed Products

12. Non-Small Cell Lung Cancer Emerging Drugs and Latest Therapeutic Advances

13. Non-Small Cell Lung Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Non-Small Cell Lung Cancer Market Outlook (In US, EU5, and Japan)

16. Non-Small Cell Lung Cancer Access and Reimbursement Overview

17. KOL Views on the Non-Small Cell Lung Cancer Market

18. Non-Small Cell Lung Cancer Market Drivers

19. Non-Small Cell Lung Cancer Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Pancreatic Adenocarcinoma Market

“Pancreatic Adenocarcinoma Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Pancreatic Adenocarcinoma Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States